These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 11700581)
1. Pneumococcal vaccination and pneumonia: even a low level of clinical effectiveness is highly cost-effective. Ament A; Fedson DS; Christie P Clin Infect Dis; 2001 Dec; 33(12):2078-9. PubMed ID: 11700581 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Ament A; Baltussen R; Duru G; Rigaud-Bully C; de Graeve D; Ortqvist A; Jönsson B; Verhaegen J; Gaillat J; Christie P; Cifre AS; Vivas D; Loiseau C; Fedson DS Clin Infect Dis; 2000 Aug; 31(2):444-50. PubMed ID: 10987703 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population. Castañeda-Orjuela C; Alvis-Guzmán N; Paternina AJ; De la Hoz-Restrepo F Vaccine; 2011 Oct; 29(44):7644-50. PubMed ID: 21854825 [TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands. Postma MJ; Heijnen ML; Beutels P; Jager JC Expert Rev Vaccines; 2003 Aug; 2(4):477-82. PubMed ID: 14711333 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Melegaro A; Edmunds WJ Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710 [TBL] [Abstract][Full Text] [Related]
7. [Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis]. Postma MJ; Heijnen ML; Beutels P; Jager JC Ned Tijdschr Geneeskd; 2002 May; 146(18):855-9. PubMed ID: 12038224 [TBL] [Abstract][Full Text] [Related]
8. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vila-Corcoles A; Salsench E; Rodriguez-Blanco T; Ochoa-Gondar O; de Diego C; Valdivieso A; Hospital I; Gomez-Bertomeu F; Raga X Vaccine; 2009 Mar; 27(10):1504-10. PubMed ID: 19171174 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden. Bergman A; Hjelmgren J; Ortqvist A; Wisløff T; Kristiansen IS; Högberg LD; Persson KM; Persson U Scand J Infect Dis; 2008; 40(9):721-9. PubMed ID: 18712627 [TBL] [Abstract][Full Text] [Related]
10. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia. Musher DM; Rueda-Jaimes AM; Graviss EA; Rodriguez-Barradas MC Clin Infect Dis; 2006 Oct; 43(8):1004-8. PubMed ID: 16983612 [TBL] [Abstract][Full Text] [Related]
11. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine. Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273 [TBL] [Abstract][Full Text] [Related]
12. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting. Mangtani P; Roberts JA; Hall AJ; Cutts FT Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694 [TBL] [Abstract][Full Text] [Related]
13. New vaccines against otitis media: projected benefits and cost-effectiveness. O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of influenza and pneumococcal vaccinations among elderly people in Japan. Cai L; Uchiyama H; Yanagisawa S; Kamae I Kobe J Med Sci; 2006; 52(3-4):97-109. PubMed ID: 16855372 [TBL] [Abstract][Full Text] [Related]
15. Pneumococcal vaccination for Indian children. Levine OS; Cherian T Indian Pediatr; 2007 Jul; 44(7):491-6. PubMed ID: 17684301 [No Abstract] [Full Text] [Related]
16. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain). Navas E; Salleras L; Gisbert R; Domínguez A; Timoner E; Ibáñez D; Prat A Vaccine; 2005 Mar; 23(17-18):2342-8. PubMed ID: 15755625 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy. Lucioni C; Mazzi S Vaccine; 2006 Mar; 24(11):1735. PubMed ID: 16356601 [No Abstract] [Full Text] [Related]
18. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Ray GT; Whitney CG; Fireman BH; Ciuryla V; Black SB Pediatr Infect Dis J; 2006 Jun; 25(6):494-501. PubMed ID: 16732146 [TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of pneumococcal conjugate vaccination in Finland. Salo H; Sintonen H; Nuorti JP; Linna M; Nohynek H; Verho J; Kilpi T Scand J Infect Dis; 2005; 37(11-12):821-32. PubMed ID: 16308215 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of hospital vaccination programs in North Carolina. Honeycutt AA; Coleman MS; Anderson WL; Wirth KE Vaccine; 2007 Feb; 25(8):1484-96. PubMed ID: 17156901 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]